Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy

NCT02019784 is registered in ClinicalTrials.gov with King's College Hospital NHS Trust as lead sponsor.

NCT NCT02019784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02019784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy
Lead sponsor
King's College Hospital NHS Trust
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2015
Completion date
October 31, 2016
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatoencephalopathy, early fatal progressive, liver cirrhosis